Shopping Cart
- Remove All
Your shopping cart is currently empty
Dirlotapide
Catalog No. T15006Cas No. 481658-94-0
Alias Slentrol, CP742033
Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.
Dirlotapide
Catalog No. T15006Alias Slentrol, CP742033Cas No. 481658-94-0
Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $750 | In Stock | |
| 5 mg | $1,530 | In Stock | |
| 10 mg | $1,980 | In Stock | |
| 25 mg | $2,970 | In Stock | |
| 50 mg | $4,150 | In Stock | |
| 100 mg | $5,580 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Dirlotapide"
Anacetrapib
MK-0859
T1928875446-37-0
Anacetrapib (MK-0859) (MK0859) is an effective, specific, reversible rhCETP and mutant CETP(C13S) inhibitor (IC50: 7.9 nM and 11.8 nM). Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.
- $34
Size
QTY
Granotapide
T31992594842-13-4In house
Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.
- $210
Size
QTY
Obicetrapib
TA-8995, TA8995, Obicetrapib (free base), Obicetrapib, AMG-899, AMG899, AMG 899
T28225866399-87-3In house
Obicetrapib (AMG-899) is an inhibitor of cholesteryl ester transfer protein.
- $195
Size
QTY
BMS-212122
UNII-0Z473OO6GB, BMS212122, BMS 212122
T30506194213-64-4In house
BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
- $350
Size
QTY
Lomitapide
BMS-201038, AEGR-733
T6267182431-12-5
Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein.
- $59
Size
QTY
Dalcetrapib
RO4607381, JTT-705
T6048211513-37-0
Dalcetrapib (RO4607381), a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
- $37
Size
QTY
NAMI-A
T16266201653-76-1
NAMI-A, a ruthenium-based compound, selectively targets tumor metastasis by inhibiting cancer cell adhesion and migration.
- $47
Size
QTY
KD-026
SLx-4090, SLx4090, SLx 4090, KD026
T27719913541-47-6
KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.
- $74
Size
QTY
Lomitapide Mesylate
BMS-201038 mesylate, AEGR-733 mesylate
T2545202914-84-9
Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.
- $37
Size
QTY
Torcetrapib
CP-529414
T2499262352-17-0
Torcetrapib (CP-529414) is a cholesteryl ester transfer protein (CETP) inhibitor designed to reduce the heterotypic transfer of cholesteryl ester from HDL to LDL and/or VLDL. It failed in phase III trials due to an excess of deaths.
- $30
Size
QTY
Select Batch
Purity:100%
ee:96.14%
Contact us for more batch information
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.Product Introduction
Bioactivity
Chemical Properties
| Description | Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation. |
| In vivo | Dirlotapide (0.5 mg/kg; oral; dogs) results in a high rate of weight loss (3.3% weekly) anorexia, emesis, and loose stools for some dogs. Dirlotapide produces weight loss by both reducing appetite (about 90% of the weight loss activity) and by increasing fecal fat excretion (about 10% of the weight loss activity).[1] Dirlotapide (0.3 mg/kg; oral; once daily; dogs) has a small but significant (P=0.018) decrease (6.16 ± 2.22%, mean ± SD) in crude fat digestibility compared with the placebo-treated food-restricted dogs, but no difference in crude protein, dry matter, or energy digestibility is observed. Dirlotapide effectively reduces appetite and energy intake without affecting nutrient digestibility, except for a minimal decrease in fat digestibility.[2] |
| Alias | Slentrol, CP742033 |
| Molecular Weight | 674.71 |
| Formula | C40H33F3N4O3 |
| Cas No. | 481658-94-0 |
Storage & Solubility Information
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 67.47 mg/mL (100 mM), Sonication is recommended.  H2O: <1 mg/mL (Insoluble) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Dirlotapide | purchase Dirlotapide | Dirlotapide cost | order Dirlotapide | Dirlotapide chemical structure | Dirlotapide in vivo | Dirlotapide formula | Dirlotapide molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.